MET overexpression

These cells exhibited markedly enhanced cytotoxicity against tumour cells overexpressing c-Met, accompanied by increased release of key effector cytokines such as interferon-γ. This research framework offers a precise, synergistic therapeutic strategy to overcome limitations in CAR-T therapy response within serous ovarian carcinoma.

It also regulated cell adhesion and migration while reducing global protein synthesis via the downregulation of the PI3K/Akt/mTOR pathway. Our results together identify miR-6850 as a tumor-suppressive miRNA in HGSOC, demonstrating its diverse anti-oncogenic actions and underscoring its potential as a prognostic biomarker and therapeutic target in ovarian cancer.

Herein, we summarize the current evidence on MET protein OE, including prognostic value, heterogeneity, and stability. We also provide key considerations for enabling optimal real-world testing of this IHC-based biomarker.

These data suggest that c-Met protein OE is associated with MET mRNA expression, shows limited overlap with other MET aberrations, and may be linked to poor prognosis in NSCLC.

Considering pasireotide's potential to target c-MET and EGFR pathways, our findings provide a strong rationale for its further preclinical validation in the treatment of TNBC. The demonstrated efficacy and safety of pasireotide in this aggressive subtype of cancer can now be evaluated through subsequent studies.

Specifically, our study demonstrated: (1) The MET gene is significantly overexpressed in THCA tissues compared to normal controls; (2) This dysregulation is closely associated with aggressive malignant phenotypes, including enhanced tumor progression, increased metastatic potential, reduced survival, and immune-suppressive characteristics; (3) Retrospective clinical case analysis indicated that the lymph node metastasis rate was significantly elevated in the MET high-expression group relative to the low-expression group; (4) RNA interference (RNAi)-mediated MET knockdown resulted in a marked decrease in the migratory and invasive capacities of thyroid cancer cells in vitro. Collectively, these findings not only identify MET as a robust molecular classifier for THCA but, more critically, uncover its therapeutic potential as an actionable target within the HGF/c-MET axis for refractory THCA, providing both experimental evidence and a theoretical framework for developing precision diagnostic and therapeutic strategies.

P2, N=270, Active, not recruiting, AbbVie | Trial primary completion date: Oct 2025 --> Jul 2026

P1, N=30, Terminated, Regeneron Pharmaceuticals | Phase classification: P1/2 --> P1 | Trial completion date: Oct 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Oct 2025; Sponsor decision

P=N/A, N=9, Not yet recruiting, Beijing Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University

P=N/A, N=64, Not yet recruiting, Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University

Despite the therapeutic potential of existing HGFR inhibitors, such as crizotinib, concerns regarding low potency and high toxicity require safer alternatives...Highly potent candidates underwent molecular docking, identifying venetoclax (S-score: -8.78, RMSD: 1.32), LSM-5313 (S-score: -8.50, RMSD: 1.89), and cefoperazone (S-score: -8.24, RMSD: 1.82) as the lead compounds...Overall, this multi-tiered computational approach offers reliable, mechanistically supported candidates for HGFR inhibition. The identified FDA-approved drugs represent promising, non-toxic therapeutic options for ovarian cancer, encouraging further preclinical and clinical investigation.

Additionally, it examines current therapeutic approaches targeting c-Met, including small molecule inhibitors, monoclonal antibodies, and combination therapies designed to overcome resistance. The discussion extends to future challenges in c-Met inhibition, highlighting the need for innovative therapeutic strategies and combination regimens to enhance efficacy and mitigate resistance and thus the review emphasizes the transformative potential of c-Met-targeted therapies in advancing cancer treatment.